Abzu
Abzu is a company founded in 2018 with offices in Copenhagen, Denmark, and Barcelona, Spain, specializing in trustworthy, explainable AI for pharmaceutical research and development. Their proprietary AI technology, the QLattice®, enables data-driven drug design, particularly for RNA therapeutics such as siRNAs, anti-miRs, and ASOs. Abzu's AI-guided drug design process incorporates factors like thermodynamics, genetic variation, and drug properties to maximize the success rate of drug candidates, reducing design cycles and project overhead. They offer a one-stop solution from compound design to in vitro validation, leveraging curated data and predictive models to design compounds with higher likelihoods of success. Their approach emphasizes transparency, honesty, and autonomy, with a team of AI researchers and scientists from diverse backgrounds. Abzu has raised €10.2 million in VC funding and received the European Innovation Council Accelerator Grant, positioning them as a leader in explainable AI-driven pharma R&D innovation.
Abzu
Abzu is a company founded in 2018 with offices in Copenhagen, Denmark, and Barcelona, Spain, specializing in trustworthy, explainable AI for pharmaceutical research and development. Their proprietary AI technology, the QLattice®, enables data-driven drug design, particularly for RNA therapeutics such as siRNAs, anti-miRs, and ASOs. Abzu's AI-guided drug design process incorporates factors like thermodynamics, genetic variation, and drug properties to maximize the success rate of drug candidates, reducing design cycles and project overhead. They offer a one-stop solution from compound design to in vitro validation, leveraging curated data and predictive models to design compounds with higher likelihoods of success. Their approach emphasizes transparency, honesty, and autonomy, with a team of AI researchers and scientists from diverse backgrounds. Abzu has raised €10.2 million in VC funding and received the European Innovation Council Accelerator Grant, positioning them as a leader in explainable AI-driven pharma R&D innovation.